Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-GEA-977: ABBV-400 with fluorouracil, leucovorin, and budigalimab as first-line therapy for advanced gastric/GEJ/esophageal adenocarcinoma
CTR20250545Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan, fluorouracil, folinic acid, budigalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by AbbVie Inc.. Started Aug 2025; status: active.
02
Drugs
telisotuzumab adizutecanfluorouracilfolinic acidbudigalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20250545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250545.